Pharvaris NV is seeking to improve upon the standard-of-care for both treatment and prevention of hereditary angioedema (HAE) with its oral bradykinin B2 receptor antagonist deucrictibant, announcing on 5 September that it expects to launch a pivotal Phase III study by year’s end for a daily, extended-release formulation of its drug for prophylaxis. An immediate-release formulation is already in Phase III for treatment of HAE attacks.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?